Research programme: angiogenesis inhibitor - AsclepiX Therapeutics
Latest Information Update: 14 Jul 2016
At a glance
- Originator AsclepiX Therapeutics
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factors inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Wet age-related macular degeneration